Enzolytics, Inc. (ENZC)
- Previous Close
0.0018 - Open
0.0018 - Bid 0.0017 x --
- Ask 0.0018 x --
- Day's Range
0.0018 - 0.0019 - 52 Week Range
0.0014 - 0.0347 - Volume
2,327,975 - Avg. Volume
9,169,595 - Market Cap (intraday)
6.408M - Beta (5Y Monthly) 0.93
- PE Ratio (TTM)
-- - EPS (TTM)
-4.3800 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Enzolytics Inc., a drug development company, focuses to the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases. Its patented anti-HIV therapeutics and a proprietary methodology for producing human IgG1 monoclonal antibodies for treating infectious diseases with non-toxic passive immunotherapy. The company has clinically tested anti-HIV therapeutics. In addition, the company's proprietary cell line produces human monoclonal antibodies that target and neutralizes the HIV virus. Enzolytics Inc. is based in Plano, Texas.
enzolytics.comRecent News: ENZC
View More
Performance Overview: ENZC
Trailing total returns as of 10/11/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ENZC
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ENZC
View MoreValuation Measures
Market Cap
6.41M
Enterprise Value
6.41M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-704.70%
Return on Equity (ttm)
--
Revenue (ttm)
46.59k
Net Income Avi to Common (ttm)
-1.03M
Diluted EPS (ttm)
-4.3800
Balance Sheet and Cash Flow
Total Cash (mrq)
5.76k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
151.19k
Research Analysis: ENZC
View MoreCompany Insights: ENZC
ENZC does not have Company Insights